Central Nervous System - Study No 2

• International, phase III, placebo-controlled versus active comparator (interferon beta) study in patients with relapsing-remitting multiple sclerosis with competitive screening
• Planned target of 154 patients was achieved 2 months ahead of schedule
• 18 active sites
• Recruitment finished with 213 patients (138% of goal) done in 11 months